Literature DB >> 22439305

Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child.

Shital Poojary1, Sama Rais.   

Abstract

Bullous systemic lupus erythematosus (BSLE) is a rare subset of systemic lupus erythematosus (SLE) with bullous lesions in a case fulfilling the American Rheumatism Association (Atlanta) criteria, histologically characterized by a neutrophil-predominant infiltrate in the upper dermis with immunoglobulin (IgG, IgA, IgM) and C3 deposition at the basement membrane zone (BMZ). It often is associated with autoimmunity to type VII collagen (NC1 [noncollagenous domain 1] domain), although occasionally other antigens such as laminin 5, laminin 6, and BP230 (bullous pemphigoid antigen) have been described. Bullous systemic lupus erythematosus is extremely rare in children. We report here a case of a 9-year-old girl with BSLE as an initial presentation with lupus nephritis class III, a rare occurrence at such a young age. Despite the rarity, we suggest that BSLE should be considered in the differential diagnosis of subepidermal bullous diseases in children in view of associated potentially serious systemic manifestations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22439305

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone.

Authors:  Maria Cristina Maggio; Giovanni Corsello; Eugenia Prinzi; Rolando Cimaz
Journal:  Am J Case Rep       Date:  2017-03-29

Review 2.  Bullous systemic lupus erythematosus in females.

Authors:  Grant Sprow; Mohsen Afarideh; Joshua Dan; Matthew L Hedberg; Victoria P Werth
Journal:  Int J Womens Dermatol       Date:  2022-07-25

3.  Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature.

Authors:  Magdalena Żychowska; Aleksandra Batycka-Baran; Joanna Maj; Wojciech Baran
Journal:  Postepy Dermatol Alergol       Date:  2018-08-21       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.